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METHODS: A within trial study was designed. Survival gains
were estimated using an extraction of comparable patients from
the Saskatchewan Health Data Base. A piecewise regression
model yielded death rates adjusted on patients’ characteristics.
Resource use was collected alongside the clinical trial. Only
direct medical costs were considered. Hospital costs were calcu-
lated using French DRG costs, and the National Fee Schedule
for outpatient diagnostic procedures. All costs were in 2003
Euros. A sensitivity analysis using bootstrap was used to build a
conﬁdence interval for the Incremental Cost-Effectiveness Ratio,
and an acceptability curve. Costs and outcomes were discounted
at ﬁve percent. RESULTS: Overall mortality over the trial period
was 478 (14.4%) in the treatment group vs. 554 (16.7%) in the
placebo group (p = 0.008). Combined CV deaths and hospitali-
sations were 885 (26.7%) in the treatment group, vs. 993
(30.3%) in the placebo group (p = 0.002). The discounted gain
of survival was 3.2 weeks. The incremental cost per life year
saved was €15,382 (95% IC: €8274–€42,723). Following the
sensitivity analysis, 74% of the values of the ICER fell under a
€50,000 per life-year saved. CONCLUSIONS: In France, the
ICER compares with those of heart transplantation (€17,626)
and of rt-PAs in the prevention of thrombotic events during the
acute phase of AMI (€12,190). The main limitation of the study
is the restriction to the duration of the trial. Sub-group analysis
was not performed in the EPHESUS trial, and it was not possi-
ble to compute an ICER for severe heart failure patients, for
which one can expect a lower cost per life-year saved.
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OBJECTIVES: The health economic impact of an additional
metoprolol succinate treat-ment (METsuc) in patients with
chronic heart failure (CHF) was analyzed for “real life” treat-
ment patterns on the basis of the MERIT-HF—Trial (Metopro-
lol CR/XL Randomized Intervention Trial in Congestive Heart
Failure). METHODS: Based on the efﬁcacy data of the MERIT-
HF, a markov model was created to simulate the effectiveness of
METsuc treatment under real-life conditions. The additional
direct costs associated with METsuc were examined in relation
to the number of fatalities and of hospitalizations avoided. The
cost analysis was conducted from the perspective of the German
Statutory Health Insurance (SHI). Base year for the cost data was
2004. Probabilities were derived from the MERIT-HF—Trial.
Missing data for this approach were assessed with the help of a
focus group with eight general practitioners and cardiologists.
Further, the number of life-years gained was calculated by using
the DEALE method (Declining Exponential Approximation of
Life Expectancy). RESULTS: For the period observed (18
months), additional METsuc treatment does not lead to addi-
tional costs for the Statutory Health Insurance (SHI) in Germany.
With the application of METsuc, costs of about 3400 EUR per
fatality and almost 1800 EUR per hospitalization could be
avoided. The life expectancy of a CHF patient is 1.51 years
higher in comparison to standard treatment alone. Univariate
sensitivity analyses were conducted to demonstrate the robust-
ness of the results. CONCLUSIONS: The additional costs for
METsuc in the outpatient sector are compensated by reduced
expenditures in the inpatient sector as well as in the ﬁeld of
ambulance transportation. On the basis of the present analysis
the treatment with metoprolol succinate represents an approach
for integrated health care under a clinical as well as under an
economical perspective.
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OBJECTIVES: To evaluate the cost-effectiveness (CE) of can-
desartan for patients with chronic heart failure (CHF) in
Germany based on the CHARM (Candesartan in Heart failure:
Assessment of Reduction in Mortality and Morbidity)-
programme. METHODS: Two CE-analyses were conducted:
incremental cost-per-avoided-event and incremental cost per life-
years gained. Effectiveness data were derived from the CHARM-
programme which provided data on three treatment groups with
CHF-patients: “Added” (low left ventricular ejection fraction
(LVEF <40%), “Alternative” (LVEF <40% and patients’ ACE-
inhibitor intolerance) and “Preserved” (LVEF >40%). Besides, an
“Overall” analysis was processed. All cardiovascular events
(Hospital admissions due to worsening heart failure, cardiovas-
cular deaths, and cardiovascular procedures) were extracted.
Absolute risk reduction (ARR; only ﬁrst events counted) to
prevent/delay one event was evaluated. Cost calculation was per-
formed from the perspective of the German statutory health
insurance (SHI). Base year for costing was 2004. Only direct
costs (drug, hospital, general practitioner, specialist, ambulance,
rehabilitation) were considered. Incremental costs between can-
desartan and placebo were used building a ratio with ARR.
Long-term effectiveness was estimated calculating the incremen-
tal costs per life-year gained (LYG). LYG were generated using
the DEALE (Declining Exponential Approximation of Life
Expectancy)-approximation. RESULTS: The incremental costs
to prevent/delay a cardiovascular death or a hospital admission
were €2279 (“Added”), €2763 (“Alternative”), €31,015 (“Pre-
served”) and €7717 (“Overall”). The incremental costs per life-
year gained were 47 EUR (“Added”), 131 EUR (“Alternative”),
€11,054 (“Preserved”) and €231 (“Overall”). Sensitivity analy-
ses were conducted for all treatment groups. The results were
robust to variations of costs, discounting rates and effects. CON-
CLUSIONS: With regard to the results of the treatment groups
“Added” and “Alternative”, candesartan is a cost-effective treat-
ment option for patients with low left ventricular ejection frac-
tion in Germany.
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OBJECTIVE: To assess the economic and epidemiologic impact
of CHF in Friuli Venezia Giulia (FVG) a region of approximately
1.2 million inhabitants in the north-eastern Italy. METHODS:
All residents of FVG are registered in to Regional Health Service
(RHS) database, which keeps tracks of the use of medical care
admissions and reimbursement purposes. We selected residents
of FVG who had during year 2000 a ﬁrst CHF hospital admis-
sion and we followed them up till death, or December 31, 2004.
(we a priory excluded people who during the period 1995–1999
had a previous CVD event). Mortality was investigated by col-
lecting information from Regional Citizen Register ﬁle. We
obtained information on medical costs from electronic databases
